Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

Lynparza demonstrates survival benefit in early breast cancer, phase III trial data show

AstraZeneca and Merckannounced long-term results from the OlympiA phase III trial which showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival for people with germline BRCA-mutated HER2-negative high-risk early breast cancer.

Imlunestrant improves PFS in breast cancer, phase III data show

Eli Lilly and Co. announced results from the phase III EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader, in patients with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor.

Phase III trial shows improved PFS in treatment of CLL using pirtobrutinib

Eli Lilly and Co. announced results from the phase III BRUIN CLL-321 trial evaluating pirtobrutinib (Jaypirca), a non-covalent Bruton’s tyrosine kinase inhibitor in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a covalent BTK inhibitor.

Calquence + Venetoclax shows superior PFS in untreated CLL in AMPLIFY phase III trial

Positive results from the AMPLIFY phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.